Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 99Myelodysplastic Syndromes 56Leukemia, Myelomonocytic, Chronic 23Leukemia 17Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 10Hematologic Neoplasms 9Multiple Myeloma 8Hodgkin Disease 8Neoplasms 6Myeloproliferative Disorders 6Leukemia, Myeloid 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Sarcoma 4Primary Myelofibrosis 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Biphenotypic, Acute 4Head and Neck Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

Imatinib Mesylate 3fludarabine phosphate 2fludarabine 2Acetaminophen 2thymoglobulin 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Cyclophosphamide 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Blood Component Removal 1Azacitidine 1Antilymphocyte Serum 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Philadelphia Chromosome × Azacitidine × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡